Last reviewed · How we verify
Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma
Approved treatments
- Penpulimab kcqx · Akeso Biopharma
Penpulimab works by binding to the PD-1 protein on immune cells, blocking its interaction with the PD-L1 protein on cancer cells and allowing the immune system to attack the cancer.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma treatment landscape brief
- Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma treatment updates RSS
Frequently asked questions about Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma
What drugs treat Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma?
Tracked treatments include Penpulimab kcqx.
What is the treatment for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma?
Standard treatment for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma includes Penpulimab kcqx. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma patent cliff · Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma CI report
- Treatment: Penpulimab kcqx · Akeso Biopharma
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing